An increasing body of evidence indicates therapy dose and intensity influence the outcome of dialyzed ARF patients. However, a number of unanswered questions remain on this issue. These questions need to be addressed in future prospective, controlled trials that assess the effect of dose and intensity on outcome both within and between the various ARF renal replacement therapies, with appropriate and clinically relevant control arms. Such investigations should provide guidelines ultimately for the dialytic management of critically ill patients with ARF. (Int J Artif Organs 2002; 25: 1119-22) 
INTRODUCTION
More than a decade ago, our group described the application of dialysis quantification techniques, originally developed for end-stage renal disease (ESRD) patients, to the management of critically ill patients with acute renal failure (ARF) (1, 2) . Since that time, a number of investigations aimed at quantifying prescription and delivery of acute dialysis have been performed (3) (4) (5) (6) (7) (8) (9) (10) (11) . Many of these studies have highlighted the need to account for the significant kinetic differences that exist between stable ESRD and critically ill ARF patients (12) . The ultimate aim of quantifying dialysis dose in ARF is to determine the relationship between delivered therapy and survival, the latter of which is the subject of this editorial.
Intermittent hemodialysis studies
Clinical studies have produced conflicting results regarding the effect of treatment dose or intensity on ARF patient outcome. Gillum et al (13) reported results from a multi-center, prospective study in which the effect of dialysis intensity on survival in patients with ARF was investigated. In this trial, a total of 34 patients with diverse ARF etiologies received either "intensive" or "nonintensive" dialysis. Daily dialysis for 5-6 hours per treatment was generally prescribed in the intensive group while the regimen in the non-intensive group consisted of 5 hour treatments administered daily to every third day. Mean pre-dialysis azotemia control achieved in the two groups was very close to the target BUN and serum creatinine values of 60 and 5 mg/dL, respectively (intensive group) and 100 and 9 mg/dL, respectively (nonintensive group). Survival in the intensively treated group (41%) did not differ significantly from that in the nonintensive group (52%). A more recent investigation assessed outcome in 842 ICU ARF patients who received RRT between 1988 and 1994 (14) . When patient outcome was adjusted for illness severity, survival was correlated significantly with delivered IHD (Kt/V > 1.0 per treatment).
In a very recent study, Schiffl and colleagues assessed the effect of thrice-weekly vs daily HD on outcome in 160 ARF patients (15) . (Of note, patients who had severe hemodynamic instability were considered to be candidates only for CRRT and were not eligible for the study.) Singlepool Kt/V, derived from the Daugirdas II equation (16) , was used to estimate delivered HD dose. The treatment characteristics of the two patient groups are shown in Table  I . The cumulative (weekly) Kt/V delivered to the daily group was nearly twice that of the alternate-day group, on a mean basis. As there are kinetic benefits related solely to increased frequency (vide infra), use of a more rigorous "continuous-equivalent" kinetic approach, such as the equivalent renal clearance (EKR) (17, 18) or the standard urea clearance (19) actually would have increased the difference in delivered dose between the two groups. It should be noted that the mean time-averaged BUN was 60 mg/dL in the daily HD group while the same parameter in the alternate-day group was 104 mg/dL. Although insufficient information was provided to determine precisely the mean pre-dialysis BUN in the alternate-day group, it very likely was in the 140-145 mg/dL range. Consequently, although rigorous guidelines regarding azotemia control do not exist currently, it is clear that the control group received marginally adequate treatment at best.
With respect to outcome, the overall mortality was 37%, with the alternative-day HD group having a significantly (P=0.01) higher mortality (46%) than the daily HD group (28%). Recovery of renal function and frequency of intradialytic hypotension were also favorably impacted by daily HD. The increased frequency (and total weekly duration) of treatment in the daily HD group resulted in significantly lower ultrafiltration requirements per treatment, the most likely explanation for the decreased frequency of hypotension. The authors also reported significantly lower development of oliguria, sepsis, respiratory failure, and gastrointestinal bleeding in the daily HD group. Finally, in the logistic regression analysis, alternate-day HD (vs daily HD) was one of four clinical factors that were predictive of increased mortality. The other factors were increasing APACHE III score, oliguria, and sepsis.
Multiple benefits of increased therapy frequency have been proposed (20) . From a kinetic perspective, increasing frequency results in more efficient utilization of small solute depuration curves due to the avoidance of prolonged treatment periods during which solute concentrations are relatively low. In addition to the benefits specifically pertaining to the kinetics of solute removal, increased IHD frequency results in decreased ultrafiltration requirements per treatment. The avoidance of hypotensive episodes related to rapid ultrafiltration rates may also indirectly improve solute removal by decreasing the risk of therapy interruptions.
The above latter two studies employed a single-pool quantification technique developed specifically for the ESRD population. The equation used in these studies contains constants accounting for the effects of intradialytic urea generation and ultrafiltration on delivered dose. However, these constants were generated from ESRD patients. Therefore, extrapolation of this or any other equation developed specifically for ESRD patients to ARF patients may be problematic.
Continuous renal replacement therapy studies
Recent studies also suggest that the intensity or dose of CRRT influences outcome. Data from Storck et al (21) suggest that greater intensity of CRRT is associated with better patient outcome. In this study, patients were treated with either CAVH or CVVH such that a wide range of ultrafiltration rates was obtained. Survival was found to be significantly higher in the CVVH group than in the CAVH group, in which the mean ultrafiltration rates were 15.5 and 7.5 L/day, respectively. Whether the superior survival in the patients treated with CVVH rather than CAVH was related to the former's greater convective removal of small 1120 Therapy dose in acute dialysis In a recent study performed by Ronco and colleagues (22) , the effect of dose on outcome was assessed in 425 patients treated with CVVH. Patients were randomized to one of three groups based on dose, for which the surrogate was ultrafiltration rate normalized to body weight. The prescribed doses were 20, 35, and 45 mL/h/kg while mean delivered ultrafiltrate volumes were 31, 56, and 68 L/day. CVVH was performed in the postdilution mode with lactate-based substitution fluids. Survival was found to be significantly higher in the two higher dose groups, relative to that in the lowest dose group, with no survival difference between the two higher dose groups (Fig. 1) . Altlhough not prospectively defined as an outcome determinant, this same dose parameter appeared to influence outcome in a similar manner in a study published by Honore et al (23) .
An additional finding of the Ronco et al study relates to the effect of the timing of dialysis initiation on outcome. For all three dose groups, the mean BUN at the time of CVVH initiation was significantly lower among survivors vs non-survivors. This latter finding has been corroborated by a retrospective study performed by Gettings et al (24) . These investigators found that patients whose BUN was less than 60 mg/dL at the time of CRRT initiation had a significantly higher survival than those patients whose BUN was greater than 60 mg/dL.
SUMMARY
An increasing body of evidence indicates therapy dose and intensity influence the outcome of dialyzed ARF patients. However, a number of unanswered questions remain from the two landmark studies discussed above. With regard to the Schiffl et al study, systematic exclusion of the most critically ill patients and insufficient treatment prescription and delivery to the control group clearly lessen the impact of the study. For the Ronco et al study, the legitimacy of ultrafiltration as a dose surrogate, the ability to extrapolate the data to acute dialysis modalities other than CVVH, and the logistic concerns about higher fluid exchange rates are all valid concerns. These and other questions need to be addressed in future prospective, controlled trials that assess the effect of dose and intensity on outcome both within and between the various ARF renal replacement therapies, with appropriate and clinically relevant control arms. Such investigations should provide guidelines ultimately for the dialytic management of critically ill patients with ARF.
